[go: up one dir, main page]

NO20012058D0 - 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler - Google Patents

2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler

Info

Publication number
NO20012058D0
NO20012058D0 NO20012058A NO20012058A NO20012058D0 NO 20012058 D0 NO20012058 D0 NO 20012058D0 NO 20012058 A NO20012058 A NO 20012058A NO 20012058 A NO20012058 A NO 20012058A NO 20012058 D0 NO20012058 D0 NO 20012058D0
Authority
NO
Norway
Prior art keywords
ureido
preparation
antitumor agents
thiazole derivatives
thiazole
Prior art date
Application number
NO20012058A
Other languages
English (en)
Other versions
NO20012058L (no
Inventor
Paolo Pevarello
Raffaella Amici
Gabriella Traquandi
Manuela Villa
Anna Vulpetti
Antonella Isacchi
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of NO20012058D0 publication Critical patent/NO20012058D0/no
Publication of NO20012058L publication Critical patent/NO20012058L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/48Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20012058A 1998-10-30 2001-04-26 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler NO20012058L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9823873.6A GB9823873D0 (en) 1998-10-30 1998-10-30 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
PCT/EP1999/008307 WO2000026203A1 (en) 1998-10-30 1999-10-27 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents

Publications (2)

Publication Number Publication Date
NO20012058D0 true NO20012058D0 (no) 2001-04-26
NO20012058L NO20012058L (no) 2001-06-28

Family

ID=10841640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012058A NO20012058L (no) 1998-10-30 2001-04-26 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler

Country Status (22)

Country Link
US (2) US6863647B2 (no)
EP (1) EP1124811A1 (no)
JP (1) JP2002528538A (no)
KR (1) KR20010085984A (no)
CN (1) CN1325390A (no)
AR (1) AR023060A1 (no)
AU (1) AU771166C (no)
BR (1) BR9914868A (no)
CA (1) CA2347060A1 (no)
CZ (1) CZ20011413A3 (no)
EA (1) EA200100486A1 (no)
GB (1) GB9823873D0 (no)
HK (1) HK1041260A1 (no)
HU (1) HUP0104167A3 (no)
ID (1) ID28971A (no)
IL (1) IL142372A0 (no)
NO (1) NO20012058L (no)
NZ (1) NZ510967A (no)
PL (1) PL347506A1 (no)
SK (1) SK4752001A3 (no)
WO (1) WO2000026203A1 (no)
ZA (1) ZA200102869B (no)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (en) * 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1163236B1 (en) * 1999-03-12 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
CN1348370A (zh) 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
US6958333B1 (en) 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
RU2002111660A (ru) 1999-11-04 2003-11-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Непептидные замещенные бензотиазепины в качестве антагонистов вазопрессина
AU2001264376A1 (en) * 2000-06-15 2001-12-24 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
WO2002014305A2 (en) 2000-08-17 2002-02-21 Lumera Corporation Design and synthesis of advanced nlo materials for electro-optic applications
PT1330451E (pt) * 2000-10-27 2008-03-13 Ortho Mcneil Pharm Inc Benzimidazol-2-onas substituídas como antagonistas do receptor da vasopressina e moduladores do neuropéptido y
US6653478B2 (en) 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
NZ525892A (en) * 2000-11-27 2004-11-26 Pharmacia Italia S Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
WO2002056886A1 (en) * 2001-01-19 2002-07-25 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitors contaiing urea derivative as the active ingredient
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
SE0102440D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compound
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1438048A1 (en) * 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
EP1451173A4 (en) 2001-11-01 2005-10-26 Icagen Inc PIPERIDINE
US20030171411A1 (en) * 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
MY156407A (en) * 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
OA12788A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase.
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
EP1485348B1 (en) 2002-03-13 2008-06-11 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
SE0201194D0 (sv) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
AU2003241326B2 (en) 2002-05-02 2008-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2004002481A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
ATE548354T1 (de) 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
MXPA05002493A (es) * 2002-09-05 2005-05-27 Neurosearch As Derivados de diarilurea y su uso como bloqueadores del canal del cloro.
DE10247226A1 (de) * 2002-10-10 2004-04-22 Merck Patent Gmbh Heterocyclische Amide
DE60332475D1 (de) 2002-10-30 2010-06-17 Vertex Pharma Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
JP2007509846A (ja) * 2003-10-15 2007-04-19 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−ナフタレンおよび尿素誘導体
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
MXPA06007667A (es) * 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
KR20070043996A (ko) * 2004-07-02 2007-04-26 이코스 코포레이션 Chk1의 억제에 유용한 화합물
AU2005266312C1 (en) 2004-07-28 2011-06-16 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
NZ588431A (en) * 2004-09-17 2012-02-24 Whitehead Biomedical Inst Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
BRPI0519343A2 (pt) * 2004-12-30 2009-01-20 Janssen Pharmaceutica Nv piperazinil e piperidinil urÉias e compostos relacionados como moduladores de hidrolase de amida de Ácido graxo para o tratamento de ansiedade, dor e outras condiÇÕes
WO2006074358A1 (en) * 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006073202A1 (ja) * 2005-01-04 2006-07-13 National University Corporation Kanazawa University GSK3β阻害効果に基づくがんの抑制および抗がん剤の評価方法
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
ATE499370T1 (de) * 2005-01-19 2011-03-15 Bristol Myers Squibb Co 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen
DE602006021306D1 (no) * 2005-06-27 2011-05-26 Bristol Myers Squibb Co
ES2352796T3 (es) * 2005-06-27 2011-02-23 Bristol-Myers Squibb Company Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
US7714002B2 (en) * 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1904438B1 (en) * 2005-07-08 2012-02-29 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
JP2009500377A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー/エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
JP4960355B2 (ja) * 2005-07-14 2012-06-27 ノボ・ノルデイスク・エー/エス ウレア型グルコキナーゼ活性化剤
EA200801716A1 (ru) * 2006-01-18 2009-04-28 Амген Инк. Тиазольные соединения и их применение
DK1979326T3 (da) 2006-01-19 2013-01-07 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
WO2008011191A1 (en) * 2006-07-21 2008-01-24 Replidyne, Inc. Antibacterial heterocyclic ureas
EP2065369A4 (en) * 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) * 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008084043A1 (en) * 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
JP5226008B2 (ja) * 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー/エス ウレアグルコキナーゼアクチベーター
JP5675343B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としての尿素誘導体
CA2684950A1 (en) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
WO2009011871A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
EP2365752B1 (en) * 2008-10-29 2014-09-24 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
US20120071475A1 (en) * 2009-04-27 2012-03-22 Shionogi & Co., Ltd. Urea derivatives having pi3k-inhibiting activity
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
CA2817093A1 (en) * 2010-11-15 2012-05-24 Abbvie Inc. Nampt inhibitors
KR101445175B1 (ko) * 2011-09-16 2014-10-06 연세대학교 산학협력단 중간엽 줄기세포의 혈관내피세포로의 분화 유도를 위한 티아졸기를 함유하는 우레아 화합물
WO2013085954A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
US9102669B2 (en) 2011-12-06 2015-08-11 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
CN103387551B (zh) 2012-05-11 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 噻唑类化合物及其用途
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP5934658B2 (ja) * 2013-01-29 2016-06-15 Jxエネルギー株式会社 イミド−ウレア化合物及びその製造方法、グリース用増ちょう剤並びにグリース組成物
US20170298056A1 (en) * 2014-05-08 2017-10-19 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of hiv-1 entry and methods of use thereof
WO2016008433A1 (en) 2014-07-17 2016-01-21 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
WO2017027984A1 (en) * 2015-08-20 2017-02-23 Simon Fraser University Compounds and methods for treatment of cancer by inhibiting atg4b and blocking autophagy
CN107176951A (zh) * 2016-03-11 2017-09-19 恩瑞生物医药科技(上海)有限公司 一种脲类化合物、其制备方法及其医药用途
US20190330167A1 (en) * 2016-06-21 2019-10-31 The Walter And Eliza Hall Institute Of Medical Research Activators of hiv latency
EP3481810A4 (en) 2016-07-11 2019-05-29 Baruch S. Blumberg Institute SUBSTITUTED AMINOTHIAZOLE
US11174253B2 (en) 2017-08-02 2021-11-16 Alphala Co., Ltd. Compound and pharmaceutical composition containing the same
IL273428B2 (en) 2017-09-22 2023-09-01 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Prmt5阻害剤としてのヘテロ環式化合物
US11325900B2 (en) 2018-01-15 2022-05-10 Aucentra Holdings Pty Ltd 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
US11970474B2 (en) * 2018-03-01 2024-04-30 Thomas Helledays Stiftelse För Medicinsk Forskning Substituted benzodiazoles and use thereof in therapy
JP7279063B6 (ja) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Pd1/pd-l1相互作用/活性化の阻害剤としての二環式化合物
GB201809050D0 (en) * 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
WO2019241311A1 (en) 2018-06-11 2019-12-19 Northeastern University Selective ligands for modulation of girk channels
EP4487909A3 (en) 2018-06-12 2025-03-19 vTv Therapeutics LLC Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
FI3837256T3 (fi) * 2018-08-17 2023-05-15 Novartis Ag Ureayhdisteitä ja koostumuksia smarca2/brm-atpaasiestäjinä
AU2020268814A1 (en) 2019-05-03 2021-12-16 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP2022536755A (ja) * 2019-06-14 2022-08-18 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
JP2022538348A (ja) * 2019-06-28 2022-09-01 アールティーアイ インターナショナル Cb1アロステリック調節因子としての尿素誘導体
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
AU2020371727A1 (en) 2019-10-24 2022-05-26 Pierre Fabre Medicament Inhibitors of RAF kinases
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181722A1 (en) 2020-06-08 2021-12-16 Jing TENG Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
WO2022150585A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
AU2022261117A1 (en) 2021-04-23 2023-11-23 Pierre Fabre Medicament Treatment of cancer with a raf inhibitor
EP4422619A1 (en) * 2021-10-29 2024-09-04 Eisbach Bio GmbH Inhibitors of viral helicases binding to a novel allosteric binding site
CN118974036A (zh) 2022-02-03 2024-11-15 皮埃尔法布雷医药公司 Raf激酶的抑制剂
JP2025066196A (ja) * 2022-03-14 2025-04-23 国立大学法人東北大学 認知機能改善剤
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
CN117186026B (zh) * 2023-08-28 2025-07-15 南通华祥医药科技有限公司 含噻唑甲氧基苯基联硫脲基团的酰胺化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH451156A (de) * 1962-09-18 1968-05-15 Ciba Geigy Verfahren zur Herstellung des neuen N-(2-Chlor-äthyl)-N'-(5-nitro-thiazolyl-2)-harnstoffes
OA01933A (fr) * 1965-04-06 1970-02-04 Pechiney Saint Gobain Dérivés du thiazole.
FR7428M (no) * 1968-05-06 1969-11-12
BE754783A (fr) * 1969-08-15 1971-02-12 May & Baker Ltd Derives thiazolyl a usage herbicide leur preparation et les compositions qui les contiennent
HU168393B (no) 1973-11-09 1976-04-28
ZA747255B (en) * 1973-11-30 1975-11-26 Ici Ltd Herbicidal heterocyclic compounds
JPS57136579A (en) * 1981-01-21 1982-08-23 Mitsui Toatsu Chem Inc Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
HU209839B (en) 1989-04-13 1994-11-28 T Kom Za Promishlena Mikrobiol Process for producing ureido-thiazol derivatives and pharmaceutical compositions containing them
WO1997040028A1 (en) * 1996-04-23 1997-10-30 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
SI0928790T1 (en) * 1998-01-02 2003-06-30 F. Hoffmann-La Roche Ag Thiazole derivatives

Also Published As

Publication number Publication date
CA2347060A1 (en) 2000-05-11
BR9914868A (pt) 2001-07-03
SK4752001A3 (en) 2002-02-05
NZ510967A (en) 2003-10-31
HK1041260A1 (zh) 2002-07-05
WO2000026203A1 (en) 2000-05-11
KR20010085984A (ko) 2001-09-07
US6863647B2 (en) 2005-03-08
AU1044700A (en) 2000-05-22
CZ20011413A3 (cs) 2001-09-12
US20040157827A1 (en) 2004-08-12
AU771166C (en) 2005-01-13
EA200100486A1 (ru) 2001-12-24
GB9823873D0 (en) 1998-12-30
AU771166B2 (en) 2004-03-18
EP1124811A1 (en) 2001-08-22
US20030187040A1 (en) 2003-10-02
AR023060A1 (es) 2002-09-04
IL142372A0 (en) 2002-03-10
ZA200102869B (en) 2001-10-10
ID28971A (id) 2001-07-19
HUP0104167A3 (en) 2003-12-29
JP2002528538A (ja) 2002-09-03
CN1325390A (zh) 2001-12-05
PL347506A1 (en) 2002-04-08
HUP0104167A2 (hu) 2002-03-28
NO20012058L (no) 2001-06-28

Similar Documents

Publication Publication Date Title
NO20012058L (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20012057L (no) 2-amino-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
DK1202733T3 (da) 3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler
NO20020687L (no) 3(5)-ureido-pyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler
NO963506D0 (no) 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler
DK1204649T3 (da) Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
NO993003D0 (no) Sulfonamid-derivater, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenter
NO20015477D0 (no) 4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler
DK0740668T3 (da) Tetracykliske derivater, fremgangsmåde til deres fremstilling og deres anvendelse
DK1083171T3 (da) Pyrazolinderivater, deres fremstilling og anvendelse som medikamenter
NO20020811D0 (no) Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
NO20011503L (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
NO20005146D0 (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20016038L (no) Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme
NO20025150L (no) 2-acylindolderivater og deres anvendelse som antitumormidler
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
NO985307D0 (no) Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvendelse som antitumor- og antivirale midler
DK0915845T3 (da) Acryloylsubstituerede distamycinderivater, fremgangsmåde til fremstilling deraf og anvendelse som antitumormidler og antivirale midler
NO20001781D0 (no) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO20010219L (no) Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel
NO20002959L (no) Echinocandinderivater, fremgangsmÕte for fremstilling av slike og deres anvendelse som anti-soppmidler
NO20001782L (no) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO20033965L (no) Caloporosidderivater, fremgangsmåte for deres fremstilling og deres anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application